15 Skyline Drive
About Acorda TherapeuticsAcorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.
Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.
Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.
In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
Ron Cohen, M.D., President and CEO Andrew R. Blight, Ph.D., Executive Vice President, Research & Development Mary Fisher, Vice President, Marketing and Strategic Planning Elliott A. Gruskin, Ph.D., Vice President, Research & Development Mitchell Katz, Ph.D., Vice President, Clinical Programs David Lawrence, Vice President, Finance Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director Harold Safferstein, Ph.D., J.D., Vice President, Business Development
Last Updated: 05-09-03
499 articles with Acorda Therapeutics
Acorda Therapeutics, Inc. today announced that the European Medicines Agency (EMA) has completed formal validation of Acorda’s Marketing Authorization Application (MAA) for INBRIJA.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
3/9/2018Martin Shkreli's actions were brash and often bizarre, but served as a catalyst for the pharma pricing debate.
Acorda Therapeutics, Inc. today announced that it has entered into a cooperation agreement with Scopia Capital Management LP.
INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.
AMPYRA (dalfampridine) Extended Release Tablets, 10 mg - For the quarter ended December 31, 2017, the Company reported AMPYRA net revenue of $167.2 million compared to $132.3 million for the same quarter in 2016.
Acorda will host a conference call and webcast to report its fourth quarter 2017 financial results and pipeline updates on Thursday, February 15 at 8:30 a.m. ET.
All of the recent problems have caused the company's largest shareholder to push for a sale.
Rumors that Acorda was considering a sale drove company stock up about 12 percent on Friday, Jan. 5, to hit $23.55.
Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference
Unaudited 2017 full-year net sales were $542 million, an increase of approximately 10% from 2016.
INBRIJA is an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.
There were five fatalities out of seven patients with sepsis, all in the tozadenant group.
In return for the payment to Acorda, HCR obtains the right to receive royalty revenue on FAMPYRA payable by Biogen, up to an agreed upon threshold of royalties.
Acorda Therapeutics updated its Phase III clinical trial of tozadenant for Parkinson's disease.
AMPYRA (dalfampridine) Extended Release Tablets, 10 mg - For the quarter ended September 30, 2017, the Company reported AMPYRA net revenue of $132.6 million compared to $128.8 million for the same quarter in 2016.